Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCCCG-AML2020 timed-sequential chemotherapy for childhood AML
ChiCTR2000038039Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of cladribine and sorafenib in acute myeloid leukemia (AML) (3 arms), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoints: event free survival and overall survival. Started Sep 2020; status: recruiting.
02
Drugs
cladribinesorafenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2000038039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000038039.